CN105188705A - 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 - Google Patents

包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 Download PDF

Info

Publication number
CN105188705A
CN105188705A CN201480025177.5A CN201480025177A CN105188705A CN 105188705 A CN105188705 A CN 105188705A CN 201480025177 A CN201480025177 A CN 201480025177A CN 105188705 A CN105188705 A CN 105188705A
Authority
CN
China
Prior art keywords
alkyl
substituted
methyl
aromatic ring
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480025177.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·格雷姆贝卡
T·切尔皮基
德米特里·博尔金
J·赫斯
D·孙
X·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CN105188705A publication Critical patent/CN105188705A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480025177.5A 2013-03-13 2014-03-10 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 Pending CN105188705A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CN105188705A true CN105188705A (zh) 2015-12-23

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480025177.5A Pending CN105188705A (zh) 2013-03-13 2014-03-10 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法

Country Status (11)

Country Link
US (4) US9216993B2 (enExample)
EP (1) EP2968342B1 (enExample)
JP (2) JP2016512514A (enExample)
KR (1) KR20150130389A (enExample)
CN (1) CN105188705A (enExample)
AU (1) AU2014249233A1 (enExample)
BR (1) BR112015022602A2 (enExample)
CA (1) CA2904612A1 (enExample)
IL (1) IL241193A0 (enExample)
MX (1) MX2015011576A (enExample)
WO (1) WO2014164543A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152784A (zh) * 2016-03-16 2019-01-04 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987A (zh) * 2016-03-16 2019-04-16 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
CN109743875A (zh) * 2016-06-10 2019-05-10 生命医药公司 Menin-mll相互作用的抑制剂
CN110204552A (zh) * 2018-02-28 2019-09-06 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN110248946A (zh) * 2016-12-15 2019-09-17 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
CN110691779A (zh) * 2017-03-24 2020-01-14 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CN113677341A (zh) * 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN114929705A (zh) * 2020-05-28 2022-08-19 诺华公司 Mll1抑制剂及抗癌剂
CN115003677A (zh) * 2019-11-29 2022-09-02 大鹏药品工业株式会社 对kras g12d突变具有抑制活性的化合物
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ706857A (en) * 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
BR112015022602A2 (pt) 2013-03-13 2017-07-18 Univ Michigan Regents composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) * 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017132398A1 (en) * 2016-01-26 2017-08-03 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia
US10899738B2 (en) 2016-05-02 2021-01-26 The Regents Of The University Of Michigan Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
BR112020012461A2 (pt) * 2017-12-20 2020-11-24 Janssen Pharmaceutica Nv inibidores exo-aza espiro da interação menin-mll
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CA3108449A1 (en) * 2018-08-08 2020-02-13 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
JP2022502409A (ja) 2018-10-03 2022-01-11 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 低分子メニン阻害剤
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
MX2021006696A (es) * 2018-12-06 2021-07-07 Daiichi Sankyo Co Ltd Derivado de cicloalcano-1,3-diamina.
EP3897630B1 (en) 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
US20240400564A1 (en) 2021-05-14 2024-12-05 Syndax Pharmaceuticals, Inc Inhibitors of the menin-mll interaction
AU2022286467A1 (en) 2021-06-01 2024-01-25 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
JP2024525145A (ja) 2021-06-17 2024-07-10 ヤンセン ファーマシューティカ エヌ．ベー． がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
JP2025501287A (ja) * 2021-12-31 2025-01-17 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Ｍｅｎｉｎ阻害剤及びその用途
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153556A1 (en) * 2001-09-06 2003-08-14 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20110065690A1 (en) * 2009-09-04 2011-03-17 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
US8207174B2 (en) * 2007-01-22 2012-06-26 4Sc Ag Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
AU2009291783A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
EP2459533A4 (en) * 2009-07-30 2013-01-16 Univ Singapore SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
BR112015022602A2 (pt) 2013-03-13 2017-07-18 Univ Michigan Regents composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153556A1 (en) * 2001-09-06 2003-08-14 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US8207174B2 (en) * 2007-01-22 2012-06-26 4Sc Ag Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments
US20110065690A1 (en) * 2009-09-04 2011-03-17 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152784B (zh) * 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987A (zh) * 2016-03-16 2019-04-16 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109152784A (zh) * 2016-03-16 2019-01-04 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109640987B (zh) * 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN114539284A (zh) * 2016-03-16 2022-05-27 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
CN109743875A (zh) * 2016-06-10 2019-05-10 生命医药公司 Menin-mll相互作用的抑制剂
CN109743875B (zh) * 2016-06-10 2022-04-29 生命医药有限责任公司 Menin-mll相互作用的抑制剂
CN109689663B (zh) * 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634B (zh) * 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663A (zh) * 2016-09-14 2019-04-26 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN110248946A (zh) * 2016-12-15 2019-09-17 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
CN110248946B (zh) * 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
CN110691779A (zh) * 2017-03-24 2020-01-14 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN110204552A (zh) * 2018-02-28 2019-09-06 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CN113677341A (zh) * 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
CN115003677A (zh) * 2019-11-29 2022-09-02 大鹏药品工业株式会社 对kras g12d突变具有抑制活性的化合物
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CN114929705A (zh) * 2020-05-28 2022-08-19 诺华公司 Mll1抑制剂及抗癌剂
CN114929705B (zh) * 2020-05-28 2024-09-13 诺华公司 Mll1抑制剂及抗癌剂
US12371434B2 (en) 2020-05-28 2025-07-29 China Novartis Institutes For Biomedical Research Co., Ltd. MLL1 inhibitors and anti-cancer agents
CN116199633A (zh) * 2022-12-27 2023-06-02 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法

Also Published As

Publication number Publication date
EP2968342A4 (en) 2016-07-27
AU2014249233A1 (en) 2015-09-24
US10160769B2 (en) 2018-12-25
US9505782B2 (en) 2016-11-29
US9505781B2 (en) 2016-11-29
US20140275070A1 (en) 2014-09-18
JP2018115214A (ja) 2018-07-26
KR20150130389A (ko) 2015-11-23
US9216993B2 (en) 2015-12-22
US20170253611A1 (en) 2017-09-07
US20160046647A1 (en) 2016-02-18
BR112015022602A2 (pt) 2017-07-18
CA2904612A1 (en) 2014-10-09
WO2014164543A1 (en) 2014-10-09
MX2015011576A (es) 2016-05-16
IL241193A0 (en) 2015-11-30
JP6670885B2 (ja) 2020-03-25
EP2968342A1 (en) 2016-01-20
US20160137665A1 (en) 2016-05-19
JP2016512514A (ja) 2016-04-28
EP2968342B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
CN105188705A (zh) 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法
TWI863945B (zh) 2-側氧基喹唑啉衍生物作為甲硫胺酸腺苷基轉移酶２ａ抑制劑
ES3036496T3 (en) Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
KR101749192B1 (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
CN103974948B (zh) 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑
CN102816162B (zh) 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
US11718601B2 (en) Pyridinyl substituted oxoisoindoline compounds
BR112016008276B1 (pt) derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
CN103958502A (zh) 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
TW202322796A (zh) 靶向p53突變體的化合物
BR112016012844B1 (pt) Composto e composições farmacêuticas
KR20230112605A (ko) 키나아제 억제제 및 그의 용도
WO2024255782A1 (zh) 双环衍生物parp抑制剂及其用途
WO2022148196A1 (zh) 多激酶抑制剂及其用途
JP2005526764A (ja) ピリミジン化合物
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN112543757A (zh) 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
WO2023011446A1 (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
TW202432545A (zh) 可活化sting之雜環化合物
WO2025252241A1 (zh) 一种大环衍生物及其用途
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物
WO2021168521A1 (en) Inhibitors of necroptosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151223

WD01 Invention patent application deemed withdrawn after publication